Trials / Completed
CompletedNCT01037179
An Open-Label, Long-Term Study With AL-4943A Ophthalmic Solution, 0.2% in Patients With Allergic Conjunctivitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 110 (actual)
- Sponsor
- Alcon Research · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to assess safety and efficacy of long-term use of AL-4943A (Olopatadine Hydrochloride Ophthalmic Solution, 0.2%) in patients with allergic conjunctivitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Olopatadine Hydrochloride Ophthalmic Solution, 0.2% |
Timeline
- Start date
- 2010-02-01
- Primary completion
- 2010-05-01
- Completion
- 2010-05-01
- First posted
- 2009-12-22
- Last updated
- 2014-08-04
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01037179. Inclusion in this directory is not an endorsement.